Information:
Error:
ID
34329
Description
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection; ODM derived from: https://clinicaltrials.gov/show/NCT01147107
Link
https://clinicaltrials.gov/show/NCT01147107
Keywords
Versions (1)
- 1/16/19 1/16/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 16, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Hepatitis C, Chronic NCT01147107
Eligibility Hepatitis C, Chronic NCT01147107
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C, Chronic NCT01147107
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
hiv infected patients, age >18 years, meet vietnam guideline to begin art (cd4 count < 350 cells/mm3 and/or who stage iii or iv disease)
boolean
ID.2
Item
hepatitis c infection as documented by positive hcv antibodies and a detectable serum hcv rna level
boolean
ID.3
Item
ast and alt ≤ 2 x uln (≤ 80 u/l)
boolean
ID.4
Item
estimated creatinine clearance ≥ 60 ml/min
boolean
ID.5
Item
any prior art
boolean
ID.6
Item
positive hepatitis b surface antigen
boolean
ID.7
Item
clinical evidence of de-compensated cirrhosis (ascites, encephalopathy, esophageal bleeding)
boolean
ID.8
Item
requirement for acute therapy for other aids-defining illness within 14 days prior to study entry
boolean
ID.9
Item
currently on rifampicin therapy
boolean
ID.10
Item
in the first trimester of pregnancy, intent to become pregnant, or breast feeding during the study period
boolean